Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
This research study is investigating a new treatment approach for extrahepatic cholangiocarcinoma, a type of bile duct cancer that affects ducts outside the liver and cannot be removed by surgery. The study combines a local heating treatment called intraductal radiofrequency ablation (ID-RFA), which helps clear the bile ducts, with standard chemotherapy (Gemcitabine and Cisplatin) and a new immunotherapy drug called Durvalumab. Researchers want to see if adding RFA to the chemotherapy and Durvalumab might be more effective at fighting the cancer than current treatments. This trial is in its second phase, meaning it's still an early study, and will involve patients who have already had RFA and stenting to relieve bile duct blockages. The goal is to improve anti-cancer activity for these patients.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is about an important type of cancer found in the bile ducts outside the liver, called extrahepatic cholangiocarcinoma. For some people, this cancer can't be completely removed with surgery. In these cases, doctors look for other ways to treat it and slow its growth.
This study will combine a few different treatments that are already used. First, there's a procedure called intraductal radiofrequency ablation, or ID-RFA. This uses heat directly inside the bile ducts to destroy cancer cells and help keep the ducts open. Patients taking part in this study will have already had this treatment and a stent placed to help with any blockages. After that, they will receive standard chemotherapy drugs called Gemcitabine and Cisplatin. On top of this, they'll also get a newer medicine called Durvalumab, which is a type of immunotherapy that helps your body's immune system fight cancer.
The main idea behind this research is to see if putting all these treatments together – ID-RFA, chemotherapy, and Durvalumab – works better at fighting the cancer than just using chemotherapy alone. Doctors are hoping this combination will be more powerful against the cancer cells. This is a Phase 2 study, which means it's an early stage of research to check if the treatment is safe and shows promising results in a group of patients.
النقاط الرئيسية
- Targets bile duct cancer outside the liver that can't be surgically removed.
- Combines local heat treatment (RFA) with chemotherapy and immunotherapy (Durvalumab).
- Aims to improve cancer fighting ability for this specific patient group.
- It's a Phase 2 study, meaning it's an early look at safety and effectiveness.
- Patients will have already had RFA for bile duct blockages.
من قد يكون مؤهلاً؟
To join this study, you need to be at least 18 years old and have a confirmed diagnosis of extrahepatic cholangiocarcinoma that affects the bile ducts outside the liver and cannot be removed by surgery. Also, you must have already had an RFA procedure and a stent placed to help with any bile duct blockages, and these blockages should now be resolved.
Your medical team needs to agree that standard chemotherapy is suitable for you, and you should be healthy enough for it, apart from any temporary issues caused by bile duct blockages. Generally, you should be able to look after yourself with minimal help, have a life expectancy of at least 12 weeks, and weigh more than 30 kg (about 4 stone 10 pounds). Your blood tests for your blood count, liver, and kidney function also need to be within a certain healthy range.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك لا يقل عن 18 عامًا؟
- Do you have extrahepatic cholangiocarcinoma that can't be removed by surgery?
- Have you already had RFA and a stent placed for bile duct blockages, and are they now clear?
- Are you generally well enough for chemotherapy?
- Do you have a life expectancy of at least 12 weeks?
ماذا يتضمن المشاركة؟
If you decide to take part in this study, you will be given a combination of treatments. This includes specific chemotherapy drugs, Gemcitabine and Cisplatin, along with the drug Durvalumab. You will also be eligible for repeat RFA procedures during the study if your doctor decides it's needed.
Participation will involve regular hospital visits for treatments, check-ups, and tests to monitor your health and how you're responding to the treatment. This will include blood tests, scans, and physical examinations. The exact schedule will be explained by the study team, but it will continue for as long as the treatment is benefiting you and you are tolerating it well. Following study rules, attending all scheduled appointments, and undergoing specific examinations are important parts of your commitment.
المخاطر والفوائد المحتملة
المواقع (10)
- Uniklinik RWTH Aachenالرمز البريدي المؤكدآخن، ألمانيا· التوظيف
- Universitätsklinikum Bonnالرمز البريدي المؤكدبون، ألمانيا· التوظيف
- Universitätsklinikum Kölnالرمز البريدي المؤكدكولونيا، ألمانيا· التوظيف
- Universitätsklinikum Düsseldorfالرمز البريدي المؤكددوسلدورف، ألمانيا· التوظيف
- Krankenhaus Nordwestالرمز البريدي المؤكدفرانكفورت، ألمانيا· التوظيف
- الطب الجامعي غوتنغنالرمز البريدي المؤكدغوتينغن، ألمانيا· التوظيف
- الجامعة الطبية في هانوفرالرمز البريدي المؤكدهانوفر، ألمانيا· التوظيف
- UKSH Campus Lübeckالرمز البريدي المؤكدلوبيك، ألمانيا· التوظيف
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainzالرمز البريدي المؤكدماينز، ألمانيا· التوظيف
- Universitätsklinik Münsterالرمز البريدي المؤكدمونستر، ألمانيا· لم يبدأ التوظيف بعد
أسئلة شائعة
What is 'extrahepatic cholangiocarcinoma'?
It's a type of cancer that starts in the bile ducts outside the liver.
ماذا يعني مصطلح 'غير قابل للاستئصال'؟
It means the cancer can't be fully removed with surgery.
What is ID-RFA?
It's a treatment that uses heat inside the bile ducts to destroy cancer cells and clear blockages.
What is Durvalumab?
It's a type of immunotherapy that helps your body's immune system fight cancer.
هل هذا علاج جديد؟
This study combines existing treatments in a new way to see if they work better together.
كيفية معرفة المزيد
Christoph Roderburg, Prof. Dr.
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.